verall strategy and objective of the European Antibiotic Awareness Day The overall objective of the European Antibiotic Awareness Day is to support national activities aimed at raising awareness concerning the proper use of antibiotics so as to maintain the efficacy of antibiotics and avoid the eme...rgence of resistant bacteria. To this aim, ECDC has decided to produce basic campaign communication materials that communicators in EU Member States can use in devising and implementing national campaigns. At the same time, a dedicated website will be launched in July 2008. These materials aim to provide a visual identity to the campaigns across the EU member states and make the messages more recognisable and consistent, thus memorable to the target audience. The choice of supporting visuals responds to the need of making the messages accessible to parents and young people, who represent the main target for the 2008 campaign.
more
Este documento de orientación se basa en la investigación de la actividad de los medios sociales relacionados con el uso de antibióticos a nivel de la UE, así como en una encuesta sobre las actividades de los medios sociales de las organizaciones asociadas a la EAAD, en su mayoría organizacione...s paraguas de la UE de pacientes y profesionales de la salud. La investigación demostró que ya existe cierta actividad en los medios sociales sobre el uso prudente de los antibióticos y que están surgiendo algunos posibles influenciadores. Análogamente, la encuesta de los asociados de la EAAD en toda la UE mostró que los encuestados están empezando a participar activamente en las plataformas de los medios sociales.
more
Ce document d'orientation est basé sur une recherche sur les activités des médias sociaux liées à l'utilisation des antibiotiques au niveau de l'UE, ainsi que sur une enquête sur les activités des médias sociaux des organisations partenaires de l'EAAD, principalement des organisations de pat...ients et de professionnels de la santé de l'UE. La recherche a montré qu'il existe déjà une certaine activité des médias sociaux sur l'utilisation prudente des antibiotiques et que quelques influenceurs potentiels apparaissent. De même, l'enquête menée auprès des partenaires de l'EAAD à l'échelle de l'UE a montré que les personnes interrogées deviennent actives sur les plateformes de médias sociaux.
more
The toolkit offers advice on how national public health authorities could engage with primary care prescribers so as to promote appropriate and responsible use of antibiotics. The toolkit contains template materials and some suggested key messages for health professionals, idea...s for awareness raising activities, and suggested tactics for getting the messages across to both primary care providers and patients regarding prudent use of antibiotics.
more
7 April 2022. Aimed at national policymakers, public health and healthcare planners, staff working in reception centres, and healthcare staff caring for displaced persons, the information note concludes that universal testing of incoming refugees from Ukraine for tuberculosis (TB) infection is not r...ecommended. Specific groups, such as household contacts of bacteriologically confirmed pulmonary cases, or those who are immunocompromised should however be considered for TB infection testing.
more
Version 1.1. The WHO protocol has been adapted to resource-limited settings and builds on existing methodologies from the European Centre for Disease Prevention and Control (ECDC), the Global PPS project from University of Antwerp, the US Centers for Disease Control and Prevention (CDC), and the Med...icines Utilisation Research in Africa (MURIA).
Point Prevalence Surveys collects information on prescribing practices of antibiotics and other information relevant to treatment and management of infectious diseases in hospitalized patients, and complements surveillance of antimicrobial consumption.
more
Infection prevention and control (IPC) practices are of critical importance in protecting the function of healthcare services at all levels and mitigating the impact on vulnerable populations. Although the management of possible COVID-19 cases is usually guided by national policies for specific heal...thcare facilities, community transmission is currently widespread in most EU/EEA countries and the UK, therefore primary healthcare providers in the community such as GPs, dentists and pharmacists are at risk of being exposed to COVID-19.
more
This technical report presents the epidemiology of human and animal leishmaniases in the EU and its neighbouring countries and concludes that the disease remains widespread and underreported in many countries of southern Europe, northern Africa, and the Middle East and that there is a need to improv...e leishmaniasis prevention and control based on robust surveillance in humans, animals, and vectors, and to increase public awareness following a one health approach.
more
30 March 2022. Infographic
This document aims to provide guidance to healthcare facilities and healthcare providers in the European Union/European Economic Area (EU/EEA) and the United Kingdom (UK) on preparedness and infection prevention and control (IPC) measures for the management of possible and confirmed cases of COVID-1...9 in healthcare settings, including long-term care facilities (LTCFs). In addition, this document addresses the management of clinical diagnostic specimens at laboratories in the EU/EEA. This is the sixth update of the ECDC guidance on ‘Infection prevention and control and preparedness for COVID-19 in healthcare settings’, and replaces the document dated 6 October 2020.
more
Guidance Brief
Selected findings from ECDC and EMCDDA scientific guidance, 2018
Preparedness planning is essential in order to respond effectively to outbreaks, including single case occurrences of highconsequence infectious diseases (HCID), such as the importation of a viral haemorrhagic fever (VHF) case
This document provides guidance on the application of non-pharmaceutical countermeasures to minimise the spread of the 2019 novel coronavirus (2019-nCoV) in the population. Some of the measures proposed refer specifically to certain phases of the epidemic (containment or mitigation phases), and can ...be adapted depending on the assessed severity/impact of the infection. Other measures are valid for all phases of an epidemic.
The guidance is based on the current knowledge of the 2019-nCoV and evidence available on other viral respiratory pathogens, mainly the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), the Middle East Respiratory Syndrome-related coronavirus (MERS-CoV) and seasonal or pandemic influenza viruses.
more
Guiding principles for reuse are:
Respirators which have been visibly contaminated (e.g. during procedure at intubated patients, such as suction cleaning of airways, taking probes, extubation attempts, etc.) or are damaged or not fitting, should be discarded and cannot be taken for re-use or de...contamination procedures.
Respirators may be protected by a medical face mask in order to prevent soiling.
Use of new ‘expired respirators’ (manufacturers expiry date) is possible if they were properly stored until use.
more
This document aims to provide guidance to EU/EEA public health authorities, public health professionals and healthcare practitioners for the management of persons having had contact with cases of Ebola virus disease (EVD) after visiting or working in an area that is affected by EVD; also covered is ...occupational exposure to the disease
more
This threat assessment addresses the implications of the ongoing Marburg virus disease (MVD) outbreak in
Rwanda for the European Union/European Economic Area (EU/EEA). MVD is a severe disease in humans and,
although uncommon, it has the potential to cause epidemics with significant case fatality. ...All recorded MVD
outbreaks to date have originated in Africa. MVD is not an airborne disease and is considered not to be
contagious before symptoms appear. Direct contact with the blood and other body fluids of infected people
and animals or indirect contact with contaminated surfaces and materials like clothing, bedding and medical
equipment is required for transmission. The risk of infection is minimised when proper infection prevention and
control precautions are strictly followed. There is no approved treatment or vaccine for MVD; however, several
pharmaceuticals and candidate MVD vaccines are under investigation.
more